Fig. 2
From: Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma
Kaplan–Meier curves of the relapse-free survival for CD20-TLS in patients with ESCC. A. The survival rate of patients in the TLS-rich group tended to be higher than that of patients in the TLS-poor group (survival rate at 36 months: 81.8%, and 64.2%, respectively). B There was no significant difference in the survival of the patients who received neoadjuvant chemotherapy in comparison to the TLS-rich group and the TLS-poor group (survival rate at 36 months: 50.5%, and 48.7%, respectively)